New insulin combo aims to improve daily blood sugar control in type 2 diabetes
NCT ID NCT06671587
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a combination insulin drug (iGlarLixi) works better than standard insulin (Gla-100) at keeping blood sugar within a healthy range throughout the day. About 678 Chinese adults with type 2 diabetes who are not well controlled on oral medications will use a continuous glucose monitor for 20 weeks. The goal is to see if iGlarLixi helps them spend more time in the target blood sugar zone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
iGlarLixi (a combination of insulin glargine and lixisenatide)
What this could lead to
If successful, this could offer a more effective way to manage blood sugar levels in people with type 2 diabetes, potentially reducing complications.
What could go wrong
This is a Phase 4 trial, so the drugs are already approved. However, results may not apply to all populations, and side effects like low blood sugar or digestive issues are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES (T2D) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Investigational Site Number: 1560001
RECRUITINGBeijing, 100730, China